Form 4: Aprea Therapeutics CFO Buys Shares, Warrants in Private Placement

Aprea Therapeutics' SrVP/CFO John P. Hamill acquired 5,700 shares of common stock and accompanying warrants in a private placement.

Summary

• John P. Hamill, Senior Vice President, Chief Financial Officer, and Principal Financial & Accounting Officer of Aprea Therapeutics, Inc. (APRE), acquired securities.
• The acquisition involved 5,700 shares of Aprea Therapeutics' common stock at a purchase price of $0.89 per share.
• Hamill also received accompanying common warrants to purchase up to an aggregate of 5,700 additional shares.
• The transaction was part of a private placement with certain accredited investors, which closed on January 30, 2026.
• Following the transaction, Hamill beneficially owns 33,433 shares of common stock directly.
• The common warrants are immediately exercisable at an exercise price of $0.765 per share.
• The warrants are subject to limitations, preventing exercise if it would cause the holder's beneficial ownership to exceed 4.99% of outstanding common stock or 9.99% of combined voting power.
• The common warrants will expire on the second-year anniversary of the earlier of the registration statement's effective date or the date shares become eligible for sale under Rule 144.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying by a key executive typically indicates confidence in the company's future, though the transaction size is not exceptionally large.

Positives

• Insider buying by a key executive (CFO) can signal management's confidence in the company's future prospects and valuation.
• The acquisition of both common stock and warrants demonstrates a commitment to the company's long-term potential.

Risks

• The common warrants have limitations on exercise, preventing the holder from exceeding 4.99% beneficial ownership of common stock or 9.99% of combined voting power, which could limit the upside for the warrant holder.
• The value of the acquired shares and warrants is subject to market fluctuations and the future performance of Aprea Therapeutics, Inc.

Future Outlook

The common warrants are immediately exercisable, subject to certain ownership limitations, and will expire on the second-year anniversary of the earlier of the registration statement's effective date or the date the underlying shares become eligible for sale under Rule 144.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a CFO, are often interpreted by the market as a positive signal, indicating management's belief in the company's intrinsic value and future growth prospects. This transaction occurs within the broader context of capital raising activities for biotechnology companies, where private placements are a common method to secure funding.

Related Party Transactions

• The transaction involves John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr, acquiring securities from Aprea Therapeutics, Inc. in a private placement, making it a related party transaction.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The private placement provides capital to the company, which could support ongoing operations or strategic initiatives.

Next Steps

• The company may file a registration statement for the underlying shares of the common warrants.
• The eligibility of the shares underlying the common warrants for sale under Rule 144 will be a future milestone affecting their liquidity.

Key Dates

Recommendation

While insider buying by a CFO is generally a positive signal, this Form 4 filing alone does not provide sufficient comprehensive financial or operational data to warrant a 'buy' or 'sell' recommendation. It suggests management confidence but should be considered in conjunction with broader financial reports and market conditions. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal without overstating its immediate impact on the company's fundamental outlook.

Keywords

Aprea Therapeutics, APRE, Insider Trading, Form 4, Private Placement, Common Stock, Warrants, CFO, Equity Acquisition